Last Price
2.39
Today's Change
+0.06 (2.57%)
Day's Change
2.32 - 2.44
Trading Volume
3,124,961
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Michael Exton Ph.D. Dr. Michael Exton Ph.D.
Full Time Employees: 285 285
IPO Date: 2000-04-07 2000-04-07
CIK: 0001062822 0001062822
ISIN: US5288723027 US5288723027
CUSIP: 528872302 528872302
Beta: 1.36 1.36
Last Dividend: 0.00 0.00
Dcf Diff: 2.71 2.71
Dcf: -0.39 -0.39
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.